Early provision of cancer treatments that patients can afford with confidence
First written in FY2019-Q2. 22 of 24 entries say "Restated". Latest entry: FY2026.
0 other companies' latest entry also says "Restated".
- FY2026RestatedAnnual report
「Amid concerns about treatment for the aging population of cancer patients and anxiety about the growing financial burden caused by increasingly expensive new drugs, we pursued research and development based on our “modular drug discovery” approach and advanced the clinical development of each pipeline product, with the aim of providing treatments that patients can confidently recommend to family members with cancer without undue financial concerns.」
Reaffirms the goal of providing affordable treatments that can be recommended to family members against the backdrop of concerns about the financial burden of rising new-drug prices. - FY2026-H1RestatedAnnual report
「Amid concerns about treatment for the aging population of cancer patients and anxiety about the growing financial burden caused by increasingly expensive new drugs, we pursued research and development based on our “modular drug discovery” approach and advanced the clinical development of each pipeline product, with the aim of providing treatments that patients can confidently recommend to family members with cancer without undue financial concerns.」
Reaffirms the goal of providing affordable treatments that can be recommended to family members against the backdrop of concerns about the financial burden of rising new-drug prices. - FY2025-H1RestatedAnnual report
「Amid concerns about treatment for the aging population of cancer patients and anxiety about the growing financial burden caused by increasingly expensive new drugs, we pursued research and development based on our “modular drug discovery” approach and advanced the clinical development of each pipeline product, with the aim of providing treatments that patients can confidently recommend to family members with cancer without undue financial concerns.」
Reaffirms the goal of providing affordable treatments that can be recommended to family members against the backdrop of concerns about the financial burden of rising new-drug prices. - FY2024-Q3RestatedAnnual report
「As concerns grow over cancer treatment for an aging patient population and the cost of increasingly expensive new drugs, we pursued research and development based on our "module drug discovery" approach and steadily advanced the clinical development of each pipeline, with the aim of providing treatments that patients can recommend to family members with cancer without financial concerns.」
Reaffirms the goal of providing affordable treatments that can be recommended to family members against the backdrop of an aging cancer-patient population and rising new-drug prices. - FY2024-Q2RestatedAnnual report
「As concerns grow over cancer treatment for an aging patient population and the cost of increasingly expensive new drugs, we pursued research and development based on our "module drug discovery" approach and steadily advanced the clinical development of each pipeline, with the aim of providing treatments that patients can recommend to family members with cancer without financial concerns.」
Reaffirms the goal of providing affordable treatments that can be recommended to family members against the backdrop of an aging cancer-patient population and rising new-drug prices. - FY2024-Q1RestatedAnnual report
「As concerns grow over cancer treatment for an aging patient population and the cost of increasingly expensive new drugs, we pursued research and development based on our "module drug discovery" approach and steadily advanced the clinical development of each pipeline, with the aim of providing treatments that patients can recommend to family members with cancer without financial concerns.」
Reaffirms the goal of providing affordable treatments for family members against the backdrop of an aging cancer population and increasingly expensive new drugs. - FY2023ReframedAnnual report
「We recognize the research and development of anticancer drugs based on our proprietary "module drug discovery" approach, and contributing to improvements in cancer patients' quality of life through the launch of novel anticancer drugs, as a materiality.」
The previous goal of providing treatments was positioned as a sustainability materiality linked to the launch of novel anticancer drugs and improvements in patients' quality of life. - FY2023-Q3RestatedAnnual report
「As concerns grow over cancer treatment for an aging patient population and the cost of increasingly expensive new drugs, we pursued research and development based on our "module drug discovery" approach and steadily advanced the clinical development of each pipeline, with the aim of providing treatments that patients can recommend to family members with cancer without financial concerns.」
Reaffirms the goal of providing affordable treatments for family members against the backdrop of an aging cancer population and increasingly expensive new drugs. - FY2023-Q2RestatedAnnual report
「As concerns grow over cancer treatment for an aging patient population and the cost of increasingly expensive new drugs, we pursued research and development based on our "module drug discovery" approach and steadily advanced the clinical development of each pipeline, with the aim of providing treatments that patients can recommend to family members with cancer without financial concerns.」
Reaffirms the goal of providing affordable treatments for family members against the backdrop of an aging cancer population and increasingly expensive new drugs. - FY2023-Q1RestatedAnnual report
「As concerns grow over cancer treatment for an aging patient population and the cost of increasingly expensive new drugs, we pursued research and development based on our "module drug discovery" approach and steadily advanced the clinical development of each pipeline, with the aim of providing treatments that patients can recommend to family members with cancer without financial concerns.」
Reaffirms the goal of providing affordable treatments for family members against the backdrop of an aging cancer population and increasingly expensive new drugs. - FY2022RestatedAnnual report
「As concerns grow over cancer treatment for an aging patient population and the cost of increasingly expensive new drugs, we pursued research and development based on our "module drug discovery" approach and steadily advanced the clinical development of each pipeline, with the aim of providing treatments that patients can recommend to family members with cancer without financial concerns.」
Reaffirms the goal of providing affordable treatments for family members against the backdrop of an aging cancer population and increasingly expensive new drugs. - FY2022-Q3RestatedAnnual report
「Against this backdrop, as concerns grow over cancer treatment for an aging patient population and the cost of increasingly expensive new drugs, we have steadily advanced clinical development by pursuing research and development based on our "module drug discovery" approach, with the aim of providing treatments that patients can recommend to family members with cancer without financial concerns.」
Reaffirms the goal of providing affordable treatments for family members against the backdrop of an aging cancer population and increasingly expensive new drugs. - FY2022-Q2RestatedAnnual report
「Against this backdrop, as concerns grow over cancer treatment for an aging patient population and the cost of increasingly expensive new drugs, we have steadily advanced clinical development by pursuing research and development based on our "module drug discovery" approach, with the aim of providing treatments that patients can recommend to family members with cancer without financial concerns.」
Reaffirms the goal of providing affordable treatments for family members against the backdrop of an aging cancer population and increasingly expensive new drugs. - FY2022-Q1RestatedAnnual report
「As concerns grow over cancer treatment for an aging patient population and the cost of increasingly expensive new drugs, we have steadily advanced clinical development by pursuing research and development based on our "module drug discovery" approach, with the aim of providing treatments that patients can recommend to family members with cancer without financial concerns.」
Reaffirms the goal of providing affordable treatments for family members against the backdrop of an aging cancer population and increasingly expensive new drugs. - FY2021RestatedAnnual report
「As concerns grow over cancer treatment for an aging patient population and the cost of increasingly expensive new drugs, we have steadily advanced clinical development by pursuing research and development based on our "module drug discovery" approach, with the aim of providing treatments that patients can recommend to family members with cancer without financial concerns.」
Reaffirms the goal of providing affordable treatments for family members against the backdrop of an aging cancer population and increasingly expensive new drugs. - FY2021-Q3RestatedAnnual report
「While the effects of the COVID-19 pandemic continued, we steadily advanced clinical development with the aim of providing treatments that patients can recommend to family members with cancer without financial concerns.」
Reaffirms the goal of providing affordable treatments for family members with cancer while the effects of the COVID-19 pandemic continued. - FY2021-Q2RestatedAnnual report
「Despite restrictions on movement caused by the COVID-19 pandemic, we steadily advanced clinical development with the aim of providing treatments that patients can recommend to family members with cancer without financial concerns.」
Reaffirms the goal of providing affordable treatments for family members with cancer despite movement restrictions caused by the COVID-19 pandemic. - FY2021-Q1RestatedAnnual report
「Despite the impact of the COVID-19 pandemic, we steadily advanced clinical development with the aim of providing treatments that patients can recommend to family members with cancer without financial concerns.」
Reaffirms the goal of providing affordable treatments for family members with cancer despite the impact of the COVID-19 pandemic. The wording changed from "family members" in the broader sense to "family." - FY2020-Q3RestatedAnnual report
「Amid ongoing changes in market conditions in Japan and overseas, we have steadily advanced our development pipeline by pursuing research and development based on our "module drug discovery" approach, with the aim of providing at an early stage treatments that patients can recommend to family members with cancer without financial concerns.」
Reaffirms the goal of providing affordable treatments at an early stage against the backdrop of changes in market conditions in Japan and overseas. - FY2020-Q2RestatedAnnual report
「Amid ongoing changes in market conditions in Japan and overseas, we have steadily advanced clinical development by pursuing research and development based on our "module drug discovery" approach, with the aim of providing at an early stage treatments that patients can recommend to family members with cancer without financial concerns.」
Reaffirms the goal of providing affordable treatments at an early stage against the backdrop of changes in market conditions in Japan and overseas. - FY2020-Q1RestatedAnnual report
「Amid ongoing changes in the market environment, we have steadily advanced clinical development by pursuing research and development based on our "module drug discovery" approach, with the aim of providing at an early stage treatments that patients can recommend to family members with cancer without financial concerns.」
Reaffirms the goal of providing affordable treatments at an early stage against the backdrop of changes in the market environment. - FY2019RestatedAnnual report
「As concerns grow over the impact of the aging cancer population and increasingly expensive new drugs on healthcare finances, we have steadily advanced clinical development by pursuing research and development based on our "module drug discovery" approach, with the aim of providing treatments that patients can recommend to family members with cancer without financial concerns.」
Reaffirms the goal of providing affordable treatments against the backdrop of rising drug prices and concerns over healthcare finances. - FY2019-Q3RestatedAnnual report
「Amid intensifying competition in new drug development, we have steadily advanced clinical development by pursuing research and development based on our "module drug discovery" approach, with the aim of providing at an early stage treatments that patients can recommend to family members with cancer without financial concerns.」
Continues to state a policy of pursuing affordable treatments and early availability against the backdrop of intensifying competition. - FY2019-Q2First statedAnnual report
「Amid the rising cost of new drugs, we have steadily advanced clinical development by pursuing research and development based on our “modular drug discovery” approach, with the aim of providing at an early stage treatments that patients can recommend to family members with cancer without financial concern.」
Sets out a goal linking affordability with early availability against the backdrop of rising new-drug costs.